We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Liquid Biopsy Proves Effective as Biopsy for NSCLC

By LabMedica International staff writers
Posted on 13 Mar 2019
Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). More...
NSCLC accounts for about 85% of all lung cancers. As a class, NSCLCs are relatively insensitive to chemotherapy, compared to small cell carcinoma.

A liquid biopsy test is comparable to standard tissue biopsies in detection of guideline recommended biomarkers in advanced NSCLC, has a faster turn-around time, and has the potential to support identification of more patients who can be treated with targeted therapy.

Scientists at the University of Texas M. D. Anderson Cancer Center (Houston, TX, USA) and their colleagues conducted a comprehensive liquid biopsy study conducted at several participating institutions, The team used the Guardant360 liquid biopsy test that employed cell-free tumor DNA (cfDNA) in blood to test for mutations in 282 patients. The test detected seven known predictive biomarkers including genomic alterations in ROS1, BRAF, RET, MET, ALK, EGFR and ERBB2, and one prognostic biomarker, KRAS mutations.

Standard tissue sampling detected at least one of predictive biomarkers in 60 patients, while Guardant360 identified biomarkers in 77 patients. Among the remaining 193 patients who did not have one of the seven biomarkers, the liquid biopsy test found the KRAS mutation in 92 patients, compared to 24 patients with standard tissue sampling. The study reported a median turn-around time from test order to final results of nine days for the liquid biopsy test, compared to 15 days for tissue-based testing.

Vassiliki Papadimitrakopoulou, MD, a professor of Thoracic/Head and Neck Medical Oncology and the lead author of the study said, “We know that guideline-recommended testing is normally completed in only 8% of patients with NSCLC. This does not provide all the crucial information for physicians to make an informed therapy decision. This study shows that a highly sensitive and specific liquid biopsy should be part of the standard of care for these patients. Given that advanced NSCLC is often fatal, it is important we get patients on treatment at the earliest possible time. Our findings show that we can greatly reduce the amount of time between testing and initiation of therapy.” The study will be presented at the AACR Annual Meeting 2019, held March 29-April 3, in Atlanta, GA, USA.

Related Links:
University of Texas M. D. Anderson Cancer Center


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Collection and Transport System
PurSafe Plus®
New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
New
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.